

CLAIMS

We claim:

SUB B1
1. A method for administering a lipopeptide antibiotic, comprising the step of administering to a patient in need thereof a therapeutically effective amount of the lipopeptide antibiotic at a dosage interval that does not result in muscle toxicity.

SUB B2
2. The method according to claim 1, wherein the lipopeptide antibiotic is administered once every 24 hours to once weekly.

SUB B3
10 3. The method according to claim 2, wherein the lipopeptide antibiotic is administered once every 24 hours, 48 hours, 72 hours or 96 hours.

SUB B4
4. The method according to claim 1, wherein the lipopeptide antibiotic is selected from the group consisting of daptomycin, a daptomycin derivative, A54145 and a A54145 derivative.

15 5. The method according to claim 4, wherein the lipopeptide antibiotic is daptomycin.

20 6. A method for administering daptomycin, comprising the step of administering to a patient in need thereof a therapeutically effective amount of daptomycin in a dose of 3 to 75 mg/kg of daptomycin, wherein the daptomycin is administered once every 24 hours to once weekly.

SUB B5
7. The method according to claim 6, wherein the dose is 3 to 12 mg/kg.

Sub C 8. The method according to claim 7, wherein the dose is 3, 4, 5, 6,
7, 8, 9, 10, 11 or 12 mg/kg.

Sub B5 9. The method according to claim 6, wherein the dose is 10 to 25
mg/kg.

Sub C 5 10. The method according to claim 9, wherein the dose is 10, 11,
12, 13, 14, 15, 16, 20 or 25 mg/kg.

Sub B6 11. The method according to either of claim 1 or claim 6, wherein
an antibiotic other than a lipopeptide antibiotic is co-administered with the
lipopeptide antibiotic.

10 12. The method according to claim 11 wherein said lipopeptide
antibiotic is daptomycin.

Sub C 15 13. The method according to claim 11, wherein said antibiotic is
selected from the group consisting of penicillins and related drugs, carbapenems,
cephalosporins and related drugs, aminoglycosides, bacitracin, gramicidin,
mupirocin, chloramphenicol, thiampenicol, fusidate sodium, lincomycin,
clindamycin, macrolides, novobiocin, polymyxins, rifamycins, spectinomycin,
tetracyclines, vancomycin, teicoplanin, streptogramins, anti-folate agents,
sulfonamides, trimethoprim and its combinations, pyrimethamine, synthetic
antibacterials, nitrofurans, methenamine mandelate, methenamine hippurate,
20 nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide,
para-aminosalicylic acid (PAS), cycloserine, capreomycin, ethionamide,
prothionamide, thiacetazone and viomycin.

- Jew
C
cont.*
- ~~14. The method according to claim 11, wherein said antibiotic is selected from the group consisting of imipenen, amikacin, netilmicin, fosfomycin, gentamicin and teicoplanin.~~
- ~~15. The method according to claim 11, wherein said administering is via oral, subcutaneous or intravenous administration.~~
16. A method for administering daptomycin, comprising the step of administering to a patient or animal in need thereof a therapeutically effective amount of daptomycin at a dose of 3 to 75 mg/kg of daptomycin, wherein daptomycin is administered once every 24 hours.
- 10 17. The method according to claim 16, wherein the dose is 3 to 12 mg/kg.
18. The method according to claim 17, wherein the dose is 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg/kg.
19. The method according to claim 16, wherein the dose is 10 to 25 mg/kg.
- 15 20. The method according to claim 19, wherein the dose is 10, 11, 12, 13, 14, 15, 16, 20 or 25 mg/kg.
21. The method according to claim 17, wherein the dose is 25 to 75 mg/kg.
- 20 22. The method according to claim 21, wherein the dose is 25, 50 or 75 mg/kg.
- 1008244 DE2002

23. The method according to claim 16, wherein said method reduces muscle toxicity compared to administration of daptomycin at a more frequent interval than 24 hours.
24. The method according to claim 18, wherein the dose is 4 mg/kg
5 administered once every 24 hours.
25. The method according to claim 18, wherein the dose is 6 mg/kg administered once every 24 hours.
26. The method according to any one of claims 1, 6 or 16, wherein said administering is via oral, subcutaneous or intravenous administration.
- 10 27. A method for administering quinupristin/dalfopristin, comprising the step of administering to a patient in need thereof a therapeutically effective amount of quinupristin/dalfopristin at a dosage interval that does not result in muscle toxicity.
- 15 28. The method according to claim 27, wherein quinupristin/dalfopristin is administered once every 24 hours to once weekly.
29. The method according to claim 28, wherein quinupristin/dalfopristin is administered once every 24 hours, 48 hours, 72 hours or 96 hours.
- 20 30. The method according to claim 27, wherein said quinupristin/dalfopristin is administered at a dose of 7.5 to 30 mg/kg.

DRAFT

gold
A2

31. The method according to claim 27, wherein said quinupristin/dalfopristin is administered at a dose of 7.5, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 or 30 mg/kg.
- 5 32. A pharmaceutical composition comprising a single dose of daptomycin and a pharmaceutically acceptable carrier, wherein said single dose is 7 to 15 mg/kg.
- 10 33. A pharmaceutical composition comprising a single dose of quinupristin/dalfopristin and a pharmaceutically acceptable carrier, wherein said single dose is 10 to 30 mg/kg.

10082577-D20020